This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Worst Biotech CEO of 2011 Is ...

Stocks in this article: DNDN KV-A RXPC.PK CTIC EXEL APRI CYCC

BOSTON ( TheStreet) -- The Worst Biotech CEO of 2011 award goes to Mitch Gold of Dendreon (DNDN).

TheStreet's biotechnology readers have spoken, tagging Gold for the Provenge launch fiasco and subsequent pounding of Dendreon's share price. Gold took the top (dis)honor with 37% of the 1,800 votes cast in the Worst Biotech CEO of 2011 poll.

Gold actually was lauded with the Best Biotech CEO Award last year, so his fall from grace is even more breathtaking. Knowing Gold as I do, he'll work hard in 2012 to snag another Best CEO nomination -- if his angry shareholders don't kick him out first.

Runner-up with 30% of the vote was KV Pharma's (KV-A) Greg Divis Jr. for his magnificent Makena-marketing mishaps.

Third place went to Mannkind's (MNKD) Al Mann, followed by Amarin's (AMRN) Joseph Zakrzewski and Gilead Sciences' (GILD) John Martin.

Gold takes home the Nance Trophy named in recognition of David Nance, the former CEO of now bankrupt and defunct Introgen Therapeutics. Few CEOs in biotech did more to hone the fine craft of investor bamboozlement and outright incompetence as Introgen's Nance.

Gold joins a pantheon of chief executive screw-ups: Elan's (ELN) Kelly Martin, Genzyme's Henri Termeer and Dan Bradbury of Amylin Pharmaceuticals (AMLN).

Many readers admonished me for failing to nominate Cell Therapeutics (CTIC) CEO Jim Bianco. As I've said before, he's actually the Worst Biotech CEO Emeritus. Besides, Cell Therapeutics is down only 36% this year, about half that of 2010. Yes, Bianco will argue that he deserves a raise. His patsy board will undoubtedly oblige.

Rajiv Gandhi, the long-dead Indian prime minister contacted me from beyond the grave requesting I name Doug MacLellan of Radient Pharmaceuticals (RXPC) this year's Worst Biotech CEO.

I considered the request but decided MacLellan deserved some mercy. In addition to the embarrassment of boasting about holding business talks with a government official dead for 20 years, MacLellan is still recovering from the pseudo-partnership with the Mayo Clinic, Radient's massive loan default, the reluctant disclosure that its India joint venture was a bust and the delisting from the Amex.

Did I mention that Radient's stock price is down 99.5% this year?

Other worthy biotech CEO poseurs for 2011:

Adventrx Pharmaceuticals' (ANX) Brian Culley for providing the FDA with a year of laughter.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs